Leading BioSciences Announces Potential for Investigational Drug LB1148 to Treat Multiple Organ Dysfunction Syndrome in COVID-19 Patients

    NEXT STORY
    CYTOVIA Therapeutics and MACROMOLTEK to Develop Dual-Acting Natural Killer Immunotherapy Against SARS CoV2 (COVID-19)
    PREV STORY
    Tauriga Sciences Inc. and Aegea Biotechnologies Inc. Enter into Collaboration Agreement to Develop a Rapid, Multiplexed Novel Coronavirus (COVID-19) Test Designed to Exhibit Superior Performance
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Clearside Biomedical, Inc. Announces Pricing of Public Offering of Common Stock

    ALPHARETTA, Ga., Dec. 09, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical ...

    author_avatar
    NASDAQ Market News

    Pascal Biosciences Announces Optimization of Cannabinoid-Derived Drug Candidates to Kill Glioblastoma Cells

    VANCOUVER, British Columbia and SEATTLE, Nov. 05, 2018 (GLOBE NEWSWIRE) -- Pascal Biosciences Inc. ...

    author_avatar
    NASDAQ Market News

    Cesca Therapeutics Appoints Healthcare Investment Banking Veteran Joe E. Balagot as Senior Vice President of Corporate Development

    RANCHO CORDOVA, Calif., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (NASDAQ:KOOL), a ...

    author_avatar
    NASDAQ Market News